An Update on Drug-induced Liver Injury

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 3, 2012, Pages 247-259

  Devarbhavi, Harshad ^a  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

Author keywords

Causality; DILI; Drug induced; Hepatotoxicity; Liver injury

Indexed keywords

ACETYLCYSTEINE; ALKALINE PHOSPHATASE; AMIODARONE; AMOXICILLIN; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; CARNITINE; CENTRAL NERVOUS SYSTEM AGENTS; COLESTYRAMINE; DIDANOSINE; FLUCLOXACILLIN; ISONIAZID; LAMIVUDINE; LEFLUNOMIDE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; S ADENOSYLMETHIONINE; SILYMARIN; STAVUDINE; STEROID; TETRACYCLINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZALCITABINE;

ACUTE LIVER FAILURE; AGE; ALCOHOL CONSUMPTION; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; INJURY SCALE; INTRAHEPATIC CHOLESTASIS; LATENT TUBERCULOSIS; LIVER FOCAL NODULAR HYPERPLASIA; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; NONHUMAN; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; POLYPHARMACY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PRURITUS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TOXIC HEPATITIS; TUBERCULOSIS;

EID: 84866562235     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2012.05.002     Document Type: Review

References (107)

1. International drug monitoring: the role of national centres. Report of a WHO meeting. WHO Tech Rep Ser 1972, 498:1-25. WHO.
2. Edwards R.I., Aronson J.K. Adverse drug reactions: definition, diagnosis and management. Lancet 2000, 356:1255-1259.
3. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med 2006, 354:731-739.
4. Watkins P. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011, 89:788-790.
5. Pirmohamed M., James S., Meakin S., et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004, 329:15-19.
6. Meier Y., Cavallaro M., Roos M., et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005, 61:135-143.
7. De Valle M.B., Av Klinteberg V., Alem N., Olsson R., Björnsson E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006, 24:1187-1195.
8. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
9. Devarbhavi H., Dierkhising R., Kremers W.K., Sandeep M.S., Karanth D., Adarsh C.K. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010, 105:2396-2404.
10. Vuppalanchi R., Liangpunsakul S., Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 2007, 102:558-562.
11. Hussaini S.H., O'Brien C.S., Despott E.J., Dalton H.R. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur J Gastroenterol Hepatol 2007, 19:15-20.
12. Larson A.M., Polson J., Fontana R.J., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372.
13. Reuben A., Koch D.G., Lee W.M. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
14. Kumar R., Shalimar, Bhatia V., et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology 2010, 51:1665-1674.
15. Devarbhavi H., Kremers W. Fulminant hepatic failure: cause, course and predictors of outcome. Ind J Gastroenterol 2005, 24(suppl 1):A116.
16. Devarbhavi H., Karanth D., Prasanna K.S., Adarsh C.K., Patil M. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology 2011, 54:1344-1350.
17. Devarbhavi H., Dierkhising R., Kremers W.K. Antituberculosis therapy drug-induced liver injury and acute liver failure. Hepatology 2010, 52:798-799.
18. Andrade R.J., Lucena M.I., Fernández M.C., et al. Spanish group for the study of drug-induced liver disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
19. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Drug induced liver injury network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
20. Bjornsson E., Olsson R. Outcome and prognostic markers in sever drug-induced liver disease. Hepatology 2005, 42:481-489.
21. Takikawa H., Murata Y., Horiike N., Fukui H., Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009, 39:427-431.
22. Benichou Criteria of DILI. Report of an international consensus meeting. J Hepatol 1990, 11:272-276.
23. Danan G., Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-1330.
24. Fontana R.J., Seef L.B., Andrade R.J., et al. Standardization of nomenclature and causality in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010, 52:730-742.
25. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. Hepatotoxicity of antituberculosis therapy subcommittee. Am J Respir Crit Care Med 2006, 174:935-952.
26. Verma S., Kaplowitz N. Diagnosis, management and prevention of drug-induced liver injury. Gut 2009, 58:1555-1564.
27. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89:806-815.
28. Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15:241-243.
29. Zimmerman H.J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver 1999, Lippincott Williams and Wilkins, Philadelphia, PA. 2nd ed.
30. Shapiro M.A., Lewis J.H. Causality assessment and drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007, 11:477-505.
31. Senior J.R. Monitoring for hepatotoxicity: what is the predictive value of liver "function" tests?. Clin Pharmacol Ther 2009, 85:331-334.
32. Björnsson E., Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009, 50:511-517.
33. Naranjo C.A., Busto U., Sellers E.M., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
34. Maria V.A., Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997, 26:664-669.
35. Rockey D.C., Seeff L.B., Rochon J., et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126.
36. Sarda P., Sharma S.K., Mohan A., et al. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009, 129:64-67.
37. Davern T.J., Chalasani N., Fontana R.J., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141:1665-1672.
38. Lucena M.I., Camargo R., Andrade R.J., Perez-Sanchez C.J., Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001, 33:123-130.
39. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011, 8:202-211.
40. Holt M.P., Ju C. Mechanisms of drug-induced liver injury. AAPS J 2006, 8:E48-E54.
41. Abboud G., Kaplowitz N. Drug-induced liver injury. Drug Saf 2007, 30:277-294.
42. Mehal W.A., Azzaroli F., Crispe I.N. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001, 120:250-260.
43. Bjornsson E., Kalaitzakis E., Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007, 25:1411-1421.
44. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994, 12:991-1045.
45. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005, 4:489-499.
46. Shayiq R.M., Roberts D.W., Rothstein K., et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology 1999, 29:451-463.
47. Deng X., Luyendyk J.P., Ganey P.E., Roth R.A. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol Rev 2009, 61:262-282.
48. Shaw P.J., Ganey P.E., Roth R.A. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 2010, 118:7-18.
49. Björnsson E., Talwalkar J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
50. Suzuki A., Brunt E.M., Kleiner D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011, 54:931-939.
51. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000, 22:685-708.
52. Lheureux P.E., Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009, 47:101-111.
53. Goodman Z.D. Drug hepatotoxicity. Clin Liver Dis 2002, 6:381-397.
54. Lakehal F., Dansette P.M., Becquemont L., et al. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium. Chem Res Toxicol 2001, 14:694-701.
55. Iverson S., Uetrecht J.P. Identification of reactive metabolite of terbinafine. Chem Res Toxicol 2001, 14:175-181.
56. Kullack-Ublick G.A. Drug-induced Cholestatic Liver Disease 2000, Landes Bioscience, Austin (Texas).
57. Russman S., Jetter A., Kullak-Ublik G.A. Pharmacogenetics of drug-induced liver injury. Hepatology 2010, 52:748-761.
58. Zollner G., Wagner M., Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol Ther 2010, 126:228-243.
59. Molleston J.P., Fontana R.J., Lopez M.J., Kleiner D.E., Gu J., Chalasani N. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011, 53:182-189.
60. Gronhagen-Riska C., Heelstrom P.E., Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Resp Dis 1978, 118:461-466.
61. Yew W.W. Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf 2002, 25:111-133.
62. Wright J.M., Stokes E.F., Sweeney V.P. Isoniazid-induced carbamazepine toxicity and vice versa: a double drug interaction. N Engl J Med 1982, 307:1325-1327.
63. Yee D., Valiquette C., Pelletier M., Parisien I., Rocher I., Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003, 167:1472-1477.
64. Grosset J., Truffot-Pernot C., Lacroix C., Ji B. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 1992, 36:548-551.
65. Jasmer R.M., Saukkonen J.J., Blumberg H.M., et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002, 137:640-647.
66. Singla R., Sharma S.K., Mohan A., et al. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010, 132:81-86.
67. Sharma S.K., Balamurugan A., Saha P.K., Pandey R.M., Mehra N.K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002, 166:916-919.
68. Jain M.K. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007, 11:615-639.
69. Núñez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 2006, 44:S132-S139.
70. Yimer G., Ueda N., Habtewold A., et al. Pharmacogenetic and pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011, 6:e27810.
71. Mallal S., Phillips E., Carosi G., et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008, 358:568-579.
72. Cotte L., Bénet T., Billioud C., et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study. J Hepatol 2011, 54:489-496.
73. Wong W.M., Wu P.C., Yuen M.F., et al. Antituberculosis drug- related liver dysfunction in chronic hepatitis B. Hepatology 2000, 31:201-206.
74. Sulkowski M.S., Thomas D.L., Chaisson R.E., Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
75. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902.
76. Hwang S.J., Wu J.C., Lee C.N., et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997, 12:87-91.
77. Lee B.H., Koh W.J., Choi M.S., et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005, 127:1304-1311.
78. Wang J.Y., Liu C.H., Hu F.C., et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect 2011, 62:448-455.
79. Huang Y.S., Chern H.D., Su W.J., et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002, 35:883-889.
80. Bose P.D., Sarma M.P., Medhi S., Das B.C., Husain S.A., Kar P. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011, 26:312-318.
81. Roy B., Chowdhury A., Kundu S., et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001, 16:1033-1037.
82. Vuilleumier N., Rossier M.F., Chiappe A., et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006, 62:423-429.
83. Chatterjee S., Lyle N., Mandal A., Kundu S. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. Clin Pharmacol Ther 2010, 35:465-470.
84. Hautekeete M.L., Horsman Y., van Waeyenberge C. HLA-association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999, 117:1181-1186.
85. Andrade R.J., Lucena M.I., Alonso A., et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004, 39:1603-1612.
86. Lucena M.I., Molokhia M., Shen Y., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141:338-347.
87. Donaldson P.T., Daly A.K., Henderson J., et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010, 53:1049-1053.
88. Daly A.K., Donaldson P.T., Bhatnagar P., et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009, 4:816-819.
89. Lammert C., Einarsson S., Saha C., Niklasson A., Bjornsson E., Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47:2003-2009.
90. Lammert C., Bjornsson E., Niklasson A., Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
91. Hunt C.M. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology 2010, 52:2216-2222.
92. Andrade R.J., Robles M., Lucena M.I. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf 2009, 8:709-714.
93. Krivoy N., Taer M., Neuman M.G. Antiepileptic drug-induced hypersensitivity syndrome reactions. Current Drug Safety 2006, 1:289-299.
94. Sharma S.K., Singla R., Sarda P., et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50:833-839.
95. Tahao{eth}lu K., Ataç G., Sevim T., et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001, 5:65-69.
96. Roenigk H.H., Auerbach R., Maibach H., Weinstein G., Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998, 38:478-485.
97. Aithal G.P., Haugk B., Das S., Card T., Burt A.D., Record C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 2004, 19:391-399.
98. Aithal G.P. Dangerous liaisons: drug, host and the environment. J Hepatol 2007, 46:995-998.
99. Rosenberg P., Urwitz H., Johannesson A., et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007, 46:1111-1118.
100. Lee W.M., Hynan L.S., Rossaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856-864.
101. Baniasadi S., Eftekhari P., Tabarsi P. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010, 22:1235-1238.
102. Enjalbert F., Rapior S., Nouguier-Soulé J., Guillon S., Amouroux N., Cabot C. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002, 40(6):715-757.
103. Bohan T.P., Helton E., McDonald I., et al. Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001, 56:1405-1409.
104. Stapelbroek J.M., van Erpecum K.J., Klomp L.W., Houwen R.H. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 2010, 52:258-271.
105. Smith L.A., Ignacio J.R., Winesett M.P., et al. Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr 2005, 41:469-473.
106. van Roon E.N., Jansen T.L., Houtman N.M., Spoelstra P., Brouwers J.R. Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity. Drug Saf 2004, 27:345-352.
107. Giannattasio A., D'ambrosi M., Volpicelli M., Iorio R. Steroid therapy for a case of severe drug-induced cholestasis. Ann Pharmacother 2006, 40:1196-1199.